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Hypoxic-ischemic encephalopathy (HIE) is a major cause of mortality and morbidity in 
neonates, with an estimated global incidence of 3/1,000 live births. HIE brain damage is 
associated with an inflammatory response and oxidative stress, resulting in the activation 
of cell death pathways. At present, therapeutic hypothermia is the only clinically approved 
treatment available for HIE. This approach, however, is only partially effective. Therefore, 
there is an unmet clinical need for the development of novel therapeutic interventions for 
the treatment of HIE. Curcumin is an antioxidant reactive oxygen species scavenger, with 
reported anti-tumor and anti-inflammatory activity. Curcumin has been shown to attenuate 
mitochondrial dysfunction, stabilize the cell membrane, stimulate proliferation, and reduce 
injury severity in adult models of spinal cord injury, cancer, and cardiovascular disease. 
The role of curcumin in neonatal HIE has not been widely studied due to its low bioavailability 
and limited aqueous solubility. The aim of this study was to investigate the effect of 
curcumin treatment in neonatal HIE, including time of administration and dose-dependent 
effects. Our results indicate that curcumin administration prior to HIE in neonatal mice 
elevated cell and tissue loss, as well as glial activation compared to HI alone. However, 
immediate post-treatment with curcumin was significantly neuroprotective, reducing grey 
and white matter tissue loss, TUNEL+ cell death, microglia activation, reactive astrogliosis, 
and iNOS oxidative stress when compared to vehicle-treated littermates. This effect was 
dose-dependent, with 200 μg/g body weight as the optimal dose-regimen, and was 
maintained when curcumin treatment was delayed by 60 or 120 min post-HI. Cell 
proliferation measurements showed no changes between curcumin and HI alone, 
suggesting that the protective effects of curcumin on the neonatal brain following HI are 
most likely due to curcumin’s anti-inflammatory and antioxidant properties, as seen in the 
reduced glial and iNOS activity. In conclusion, this study suggests curcumin as a potent 
neuroprotective agent with potential for the treatment of HIE. The delayed application of 
curcumin further increases its clinical relevance.
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INTRODUCTION
Neonatal hypoxic-ischemic (HI) brain injury has an incidence 
of 1–3 per 1,000 live births (Rocha-Ferreira and Hristova, 2016), 
and results in almost 1 million neonatal deaths worldwide (Lawn 
et al., 2005; Rocha-Ferreira and Hristova, 2016). Approximately, 
30% of HI cases will develop lifelong disabilities, including 
cerebral palsy, seizures, and cognitive impairments (Rocha-
Ferreira and Hristova, 2016; Lundgren et al., 2018). The severity 
of such disabilities depends on the stage of gestation at which 
the HI event occurs and its duration (Sanders et  al., 2010).
The pathology of HI brain damage is characterized by an 
initial primary energy loss phase, where oxygen and glucose 
deprivation in the cell causes a drop in the mitochondrial 
oxidative phosphorylation, resulting in reduced adenosine 
triphosphate (ATP) availability, triggering excitotoxicity (Rocha-
Ferreira and Hristova, 2016), neurotoxicity (Sanders et  al., 
2010), and oxidative stress (Hope et  al., 1984; Penrice et  al., 
1997). Early after the HI insult, damaged neuronal cells stimulate 
a pro-inflammatory immune response where activated microglia 
produce cytokines such as IL-1β and TNFα, proteases, and 
complement factors (Rocha-Ferreira and Hristova, 2016).
After successful resuscitation, a short latent/recovery period 
occurs. However, during reperfusion, the majority of the oxidative 
markers are produced, and in cases of an initial prolonged HI 
insult, the primary energy failure cannot be  compensated, 
therefore, leading to a secondary energy drop (Rocha-Ferreira 
and Hristova, 2016). Inflammatory processes and continued 
excitotoxicity lead to an impaired equilibrium between pro- and 
anti-inflammatory cytokines, as well as significant damage of 
the mitochondria machinery (Peng and Greenamyre, 1998; Puka-
Sundvall et  al., 2000). This is associated with increased levels 
of hydrogen peroxide (H2O2) and nitrogen oxide (NO), 
overproduction of free radicals, and reactive oxygen species 
(ROS) which, together with the persistent inflammation, stimulate 
necrosis (Li et  al., 1998), apoptosis (Johnston et  al., 2002), and 
autophagy (Rocha-Ferreira and Hristova, 2016) cell death pathways.
Therapeutic hypothermia (TH) is the standard clinical 
treatment applied in moderate to severe injury; however, it 
does not guarantee total recovery of the treated neonates with 
effectiveness of only 55% of cases and the remaining infants 
still develop neurological deficits (Gluckman et al., 2005). Thus, 
further studies on improving TH success rate and finding 
therapeutic alternatives are urgently required.
Curcumin, the major phytochemical component of the plant 
Curcuma longa, is extracted from its rhizomes (turmeric), and 
regularly consumed in South Asian diets (Shishodia et al., 2005; 
Pescosolido et  al., 2013). Except for turmeric usage as dietary 
spice and coloring agent, curcumin has been studied for its 
therapeutic role in several pathological conditions; its effects 
have been investigated in cancer (Naksuriya et al., 2014; Ahmad 
et  al., 2016), inflammation (Kim et  al., 2003; Sandur et  al., 
2007), infections, cardiovascular diseases (Nishiyama et al., 2005; 
Liu and Hong, 2006), fibrosis, and neurological disorders 
(Spagnuolo et  al., 2016). Such pharmacological success relies 
on the phytochemical abilities of acting on many critical pathways, 
showing anti-inflammatory (Tham et  al., 2010), anti-oxidant 
(Alexandrow et al., 2012), anti-microbial (Moghadamtousi et al., 
2014), and anti-apoptotic (Yu et  al., 2010; Jaisin et  al., 2011) 
effects, as well as capability to promote stem cell differentiation 
(Gu et  al., 2012; Mujoo et  al., 2012; Chen et  al., 2014). Effects 
of curcumin on mitochondrial function have also been reported 
(Bavarsad et  al., 2018; He et  al., 2018; Hsiao et  al., 2018; 
Momekova et al., 2018; Naserzadeh et al., 2018) and furthermore, 
hormetic effects of curcumin are receiving increased attention 
(Moghaddam et  al., 2018). Curcumin pleiotropic activity is due 
to its chemical structure, and specifically to the o-methoxy 
phenolic groups (Priyadarsini and Indira, 2014), which are central 
for chemical reactions. In fact, curcumin scavenging abilities 
on ROS and free radicals (Trujillo et  al., 2014) seem to rely 
on this functional group, as well as its modulatory role on 
pro-inflammatory cytokines [tumor necrosis factor alpha (TNFα), 
interleukin (IL)1 (Alexandrow et al., 2012), and IL6 (Maheshwari 
et al., 2006)] and its inhibition of signal transducer and activator 
of transcription 3 (STAT3) phosphorylation (Maheshwari et  al., 
2006; Alexandrow et al., 2012). As STAT3 is crucial for astrocyte 
differentiation (Hong and Song, 2014), its inhibition can reduce 
reactive astrogliosis post-HI. Clinical trials have demonstrated 
remarkable safety profile and good tolerance for curcumin in 
humans at doses of 8  g/day (Dhillon et  al., 2008). Moreover, 
the small molecular weight (368.385  g/mol), and dimensions 
allow it to cross the blood-barrier (BBB) (Priyadarsini and 
Indira, 2014), increase researchers interest for curcumin application 
in neurodegenerative disorders including traumatic brain injury 
(Wu et  al., 2006), Alzheimer’s (Ray et  al., 2011; Mutsuga et  al., 
2012), and Parkinson’s (Mythri et  al., 2011) diseases.
The pathways on which curcumin acts, overlap with those 
activated after HI injury, including oxidative stress and 
inflammation. So far curcumin has been vaguely tested in 
neonatal HI injury in rats, either through oral administration 
(Cui et al., 2017) or through intraperitoneal single dose delivery 
of nanoparticle- or DMSO-dissolved curcumin (Joseph et  al., 
2018). Both studies report attenuation of damage; however, there 
is no systematic approach to dose response or long-term protection. 
In fact, Joseph et  al. report no effect of the DMSO-dissolved 
curcumin suggesting that it is only the nanoparticle-loaded 
curcumin showing protection (Joseph et  al., 2018). The aim of 
our study was to assess the short- and long term-effects of 
curcumin administered immediately after neonatal HI insult, 
to determine the lowest neuroprotective dose of the compound 
and whether delayed administration at 60 and 120 min post-HI 
would show neuroprotection. Our observations show that 
immediate or delayed administration of curcumin strongly protects 
the neonatal brain following HI insult. These protective effects 
are though not a consequence of changes in cell proliferation, 
but possibly related to alterations in STAT3 phosphorylation 
and prohibitin (PHB) protein levels. The STAT3 Y705 
phosphorylation site is responsible for the transcription properties 
of STAT3 and previous results from our group showed bilateral 
upregulation and involvement of STAT3 Y705  in neonatal HI 
brain damage (Hristova et  al., 2016). The STAT3 S727 
phosphorylation site is downstream of extracellular signal-regulated 
kinase (ERK), respectively of RAS and is responsible for 
mitochondrial survival in cancer studies (Gough et  al., 2009).
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PHB is a pleiotropic multifaceted protein and an essential 
factor in mitochondrial homeostasis, biogenesis, degradation, 
and response to stress (Peng et  al., 2015; Ande et  al., 2017; 
Hernando-Rodríguez and Artal-Sanz, 2018). In mitochondria, 
PHB acts as a scaffold protein and is thus crucial for regulation 
of mitochondrial architecture, mitochondrial dynamics, 
morphology, and biogenesis, and furthermore stabilizes the 
mitochondrial genome (Merkwirth et al., 2012; Peng et al., 2015).
Our data demonstrate that the neuroprotective effects of 
curcumin are likely the consequence of changes in the levels 
of PHB and of STAT3 phosphorylation (Y705 and S727); thus 
affecting inflammation and mitochondrial dysfunction post-HI. 
Therefore, curcumin could be  considered a potent candidate 
for neuroprotective treatment in neonatal HI brain damage.
MATERIALS AND METHODS
HI Insult
All animal experiments and care protocols were carried out 
according to the UK Animals (Scientific Procedures) Act 1986 
and approved by the Home Office (PPL70/8784). The ARRIVE 
guidelines were followed. All experiments involved postnatal 
day 7 C57/Bl6 mice (P7) bred in house.
The surgical procedures were performed as previously described 
(Hristova et  al., 2010; Kendall et  al., 2012; Lange et  al., 2014; 
Rocha-Ferreira et  al., 2015). Briefly, male and female P7 mice 
were anesthetized with isoflurane (5% induction and 1.5% 
maintenance). The left common carotid artery was permanently 
occluded with 8/0 polypropylene suture and the wound closed 
with tissue glue. The mice recovered at 36°C and were returned 
to the dam for 2  h. The pups were then placed in a hypoxia 
chamber and exposed to humidified 8% oxygen/92% nitrogen 
(3  L/min) at 36°C for 60  min, resulting in moderate to severe 
brain damage (Lange et  al., 2014; Hristova et  al., 2016).
The P7 rodent HI model, though slightly preterm, presents 
phenotypical similarities to the grey and white matter injury 
observed in humans, i.e., tissue loss, cell-death, microglia-
mediated immune response, and astrogliosis as well as alteration 
in neurobehavioral performance (Vannucci and Vannucci, 1997).
Pharmacological Treatment
Curcumin (LKT Laboratories, UK) was dissolved in 100% 
DMSO to concentrations of 20, 44, 100, 200, and 400 ug/
ul. The animals were injected 20  min before, immediately 
after, or after a 60 or 120  min delay following a 60  min HI 
insult. The animals received a single intraperitoneal injection 
of 0.5 ul/g body weight (BW) resulting in doses of 10, 22, 
50, 100, or 200 μg/g, respectively, based on previous studies 
(Shukla et  al., 2008; Zhao et  al., 2010).
Tissue Sample Preparation
The animals were sacrificed at 48  h or at 21 days post-HI by 
intraperitoneal injection of pentobarbitone and perfused with 
30  ml (for 48  h) or 90  ml (for 21 days) 4% paraformaldehyde 
in 0.1  M phosphate buffer (PB). The brains were removed, 
post fixed in 4% paraformaldehyde/0.1  M  PB for 1  h at 4°C, 
and cryoprotected in 30% sucrose/PB solution for 24  h as 
previously described (Rocha-Ferreira et al., 2015; Hristova et al., 
2016). The brains were then frozen on dry ice, cut on a cryostat 
into sequential 40 μm sections, and stored at −80°C until used.
Immunohistochemistry and  
Histological Analysis
Five sections from each brain (400  μm apart) were rehydrated 
in distilled water and stained using immunohistochemistry as 
previously described (Möller et  al., 1996). Briefly, the sections 
were incubated overnight with rat anti-CD11b αM integrin 
subunit (1:5,000, Serotec, UK), rabbit polyclonal anti-GFAP 
(1:6,000, DAKO, UK), rabbit anti-iNOS (1:500, Santa Cruz, 
USA), polyclonal rat anti-BrdU (1:400, Abcam, UK), or rabbit 
anti-myelin basic protein (MBP) (1:200, Abcam, Cambridge, 
UK) primary antibodies, for 1  h with biotinylated goat anti-
rabbit or -rat (1:100, Vector, UK) secondary antibodies, followed 
by incubation with Avidin-Biotinylated horseradish peroxidase 
Complex (Vector, UK) and visualization with diaminobenzidine/
H2O2 (Fisher Scientific, UK). The visualization for BrdU antibody 
required Co/Ni enhancement.
Five further sections from each brain with the same spacing 
were stained using Terminal transferase mediated d-UTP nick 
end labeling (TUNEL) (Roche, UK). The staining procedure 
followed the manufacturer protocol with Co/Ni enhancement.
Five more sections per brain with the same spacing were 
stained with Cresyl-Violet (Nissl).
To detect and identify the different types of proliferating 
cells following neonatal HI, we  used double labeling for BrdU 
and: rabbit polyclonal anti-IBA1 (microglia, 1:2,000, Wako, 
Japan), rabbit polyclonal anti-GFAP (astroglia, 1:6,000, DAKO, 
UK), guinea pig polyclonal anti-NG2 (oligodendrocyte precursors, 
1:400, Bill Stallcup, USA), or mouse monoclonal anti-NeuN 
(neurons, 1:25,000, Millipore, UK). The protocol was performed 
as previously described (Hristova et  al., 2010). The sections 
were covered with VectaShield (Vector) and stored in the dark 
at 4°C before use. The number of BrdU positive and the double 
positive cells was counted in three fields at ×20 magnification. 
The percentage of the double positive cells as a fraction of 
the overall number was calculated and presented.
AlphaM Score
Immunohistochemistry for αM integrin as an early microglial 
activation marker (Raivich et  al., 1999; Hristova et  al., 2010; 
Kendall et  al., 2012; Lange et  al., 2014; Rocha-Ferreira et  al., 
2015), was performed as previously described (Rocha-Ferreira 
et  al., 2015; Hristova et  al., 2016). Semi-quantitative scores 
were allocated to each brain region (cortex, pyriform cortex, 
hippocampus, striatum, thalamus, and external capsule) by two 
independent observers blinded to the treatment of the groups.
TUNEL, BrdU, and iNOS
TUNEL positive cell death or iNOS and BrdU positive cells 
were assessed at 48  h following HI through bilateral counting 
of the number of positive cells in three different optical fields 
at ×20 magnification. Cortex, pyriform cortex, hippocampus, 
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striatum, thalamus, and external capsule were assessed for 
TUNEL and BrdU. Due to the exclusive expression of iNOS 
in hippocampus, this marker was assessed only in that region. 
The counts were averaged per  animal and per group.
Optical Luminosity
The intensity of the GFAP or MBP staining in the tissue was 
assessed using optical luminosity values (Rocha-Ferreira et  al., 
2015; Hristova et al., 2016). Images for ipsilateral and contralateral 
sides were captured with a Sony AVT-Horn 3CCD color video 
camera (24 bit RGB, 760 × 570 pixel resolution) in three 
different optical fields in the regions of interest. We  used 
Optimas 6.5 software to obtain the mean and standard deviation 
(SD) for optical luminosity values (OLV). SD was subtracted 
from the mean for each image and the resulting value was 
subtracted from the values acquired for the surrounding glass 
(Möller et al., 1996). OLVs for GFAP assessment were evaluated 
in cortex, pyriform cortex, hippocampus, striatum, thalamus 
and external capsule, while for MBP assessment OLVs were 
recorded in external capsule and striatum.
Infarct Volume Measurement
The Cresyl-Violet stained sections were scanned and imported 
into Optimas 6.5 image analysis software. The areas of intact 
staining in the cortex, pyriform cortex, hippocampus, striatum, 
thalamus, and external capsule were outlined and bilaterally 
measured using Fiji Image J (NIH, USA). In the long-term 
assessment experiments the intact staining of the different 
regions as well as the whole hemisphere were outlined and 
bilaterally measured. The percentage tissue loss was then 
calculated by converting the measured injured and uninjured 
areas into square millimeters and then transformed to a volume 
through multiplication by 400  μm. The sum of these volumes 
was then used to calculate the percentage of surviving brain 
tissue as ipsilateral/contralateral × 100 (Kendall et  al., 2006).
Behavioral Assessment
The slipping test was performed at 21 days (P28) post-HI. It 
is a modification of the balance beam test (Luong et  al., 2011) 
used for evaluation of motor balance and co-ordination. This 
test detects motor deficits resulting from central nervous system 
lesions, as well as aging and genetic and pharmacological 
interventions (Luong et  al., 2011). The apparatus consists of 
a metal grid 50  cm in length, placed about 20  cm above a 
table top between the housing cage and a new clean cage. 
The starting point is the clean cage and the finish consisted 
of the housing nesting cage. The animals were allowed to walk 
freely on the grid for 1  min. The task was recorded, and the 
videos were reviewed by two team members blinded to the 
mouse groups. The number of missed steps was counted and 
presented as a percentage of the total number of steps for 
each animal. The results were then averaged per group.
At P7, the levels of testosterone in male and female mice 
do not differ (Clarkson and Herbison, 2016). However, at 21 
days, testosterone levels between male and female mice are 
different and a lot of clinical and experimental evidence suggests 
important differences between males and females, with increased 
loss of male hippocampal volume after chronic postnatal hypoxia 
(Mayoral et al., 2009; Gobinath et al., 2017). Thus, the assessments 
for 21 days took gender into account.
Western Blot Analysis
The animals were sacrificed at 1  h post HI by intraperitoneal 
injection of pentobarbitone and hippocampus was extracted 
from treated and un-treated brains and snaps frozen before 
homogenization in RIPA+ buffer (Sigma, UK) containing 10% 
protease inhibitor complex (Sigma, UK). The time point was 
chosen as coinciding with time of maximum expression of 
phosphorylated STAT3 Y705 (Hristova et al., 2016). Total protein 
was thereafter extracted from the homogenized hippocampal 
tissue as follows: the homogenized tissue was incubated with 
the RIPA+ buffer on a shaking platform on ice for 2 h, pipetting 
gently with regular intervals. Thereafter, the homogenates were 
centrifuged at 16,000  g at 4°C for 20  min and the supernatant 
containing the extracted protein collected. The protein extracts 
were re-constituted in 2 × Laemmli sample buffer (BioRad, 
UK) containing 5% β-mercaptoethanol (Sigma, UK) and boiled 
for 5  min at 100°C before separation by SDS-PAGE, using 
4–20% Mini-Protean TGX protein gels (BioRad, UK), followed 
by Semi-Dry Western blotting analysis. Approximately, 5  μg 
of protein was loaded per lane and even transfer to nitrocellulose 
membranes (0.45 μm, BioRad, UK) was assessed using Ponceau 
S staining (Sigma, UK). The membranes were blocked for 1  h 
at room temperature (RT) in 5% bovine serum albumin (BSA, 
Sigma, UK) in Tris-buffered saline (TBS) with 0.001% Tween20 
(TBS-T), followed by overnight incubation at 4°C with the 
following primary antibodies: anti-prohibitin (Abcam, UK), 
Phospho-Stat3 (Ser727) (Cell Signaling, UK and Abcam, UK), 
or Phospho-Stat3 (Tyr705) (Cell Signaling, UK and Abcam, 
UK). Thereafter, membranes were washed three times for 10 min 
in TBS-T, incubated for 1  h at RT with an HRP-labeled anti-
rabbit IgG secondary antibody (BioRad, UK), followed by five 
TBS-T washes and one final TBS wash, and thereafter they 
were visualized using ECL (Amersham, UK) and the UVP 
BioDoc-ITTM System. HRP-conjugated anti-β-actin antibody 
(1/5,000  in TBS-T, Abcam, UK) was used for internal loading 
control and densitometry analysis was carried out using ImageJ.
Statistics
Statistical significance was assessed through repeated testing 
using Mixed Linear Model with SPSS 23.0 and GraphPad Prism 
7.0 software, treating region as the repeated measure. For each 
outcome six regions of the brain were examined. It is likely 
that with repeated measures such as the observations from a 
single subject are correlated, the first stage of the analysis 
included the observations from all the regions tested in a single 
mixed model with a random subject effect, to produce an 
estimate of the treatment effect and associated inference that 
accounts for the correlations in the data arising from the repeated 
measures. Further post hoc Student t-tests were carried out to 
assess evidence for subregional differences, p  <  0.05. For 
comparison of more than two groups, we used two-way ANOVA 
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with post hoc Tukey or Bonferroni tests to assess evidence for 
subregional differences, p  <  0.05. If parametric analysis was 
inappropriate, the non-parametric Kruskal-Wallis test was used, 
followed by Bonferroni-corrected pairwise-contrasts to investigate 
differences between treatment-conditions. For each outcome, 
the main effect from the mixed linear model or the Kruskal-
Wallis test is reported, followed by the results from the individual 
regional t-tests. In our data, a main effect is the effect of an 
independent variable (treatment) on a dependent variable (damage 
marker) averaged across the levels of any other independent 
variables (brain regions). All data are presented as Mean + SEM.
RESULTS
Intraperitoneal Pre-treatment With 
Curcumin Increases the Glial Response 
Following HI-Insult in the Neonate
To determine the biological impact of pre-treatment with 
curcumin, the animals were injected intraperitoneally with 
100  μg/g BW curcumin and the effect on brain volume loss, 
TUNEL+ cell death, and on reactive astrogliosis and microglial 
activation at 48  h were examined following the HI-insult. As 




FIGURE 1 | Intraperitoneal injection of curcumin (100 μg/g BW) in P7 mice 20 min before HI does not affect tissue damage and cell death, but significantly 
increases glial response. (A) Ipsilateral forebrain Nissl staining (Cresyl-Violet, at rostral parietal level) – Quantification of ipsilateral brain tissue volume loss of DMSO 
and curcumin pre-treated animals at 48 h following HI-insult. Curcumin pre-treatment (n = 12) did not affect volume loss compared to DMSO-treated littermates 
(n = 11) (Mixed Linear Model treating region as a repeated measure p = 0.156). However significant, individual decrease (t-test) was registered in pyriform cortex 
(p = 0.04) and striatum (p = 0.02). (B) The number of TUNEL+ dying cells (per 20x eye-field) at 48 h following HI, was not affected in the curcumin pre-treated group 
compared to DMSO-treated littermates (Mixed Linear Model treating region as a repeated measure p = 0.053). (C,D) GFAP immunoreactivity at 48 h – quantification 
of the ipsilateral (C) and contralateral (D) side in optical luminosity values (OLV, Mean + SEM). Note the increased levels of GFAP immunoreactivity in the curcumin 
pre-treated animals, with significant, individual increase (t-test) in ipsilateral cortex (p = 0.002), pyriform cortex (p = 0.0001), hippocampus (p = 3×10−5), striatum 
(p = 0.038), thalamus (p = 0.026), and external capsule (p = 0.003), and contralateral pyriform cortex (p = 0.0002), hippocampus (p = 0.04), and thalamus 
(p = 0.013). Mixed Linear Model treating region as a repeated measure revealed p = 0.0001 for ipsilateral and p = 0.007 for contralateral side, respectively.  
(E) Activation of αM+ microglia – ipsilateral αM microglial activation score (Mean + SEM). Pre-treatment with 100 μg/g BW curcumin increased αM+ microglial 
activation with significant, individual increase (t-test) in hippocampus (p = 0.008) and thalamus (p = 0.03). Mixed Linear Model treating region as a repeated measure 
revealed p = 0.019. (*p < 0.05). Abbreviations: CTX, cerebral cortex; EC, external capsule; HIP, hippocampus; PYR, pyriform cortex; STR, striatum; THAL, thalamus.
Rocha-Ferreira et al. Curcumin Neuroprotection in Neonatal Hypoxia-Ischemia
Frontiers in Physiology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 1351
on brain volume loss (Figure 1A) and TUNEL+ cell death 
(Figure 1B). However, individual significant attenuation of brain 
volume loss (t-test) was observed in pyriform cortex and striatum 
(Figure 1A). Interestingly, an increase of tissue loss, although 
not significant, was observed in the hippocampus of curcumin 
treated animals. Pre-treatment with 100  μg/g BW of curcumin 
significantly increased HI-induced and predominantly ipsilateral 
reactive astrogliosis and microglial activation (Figures  1C–E). 
Compared to DMSO-treated littermates, the curcumin pre-treated 
animals revealed more GFAP-immunoreactivity (Figures 1C,D). 
Assessment across the different forebrain regions through Mixed 
Linear Model treating region as a repeated measure revealed 
a clear increase on the ipsilateral, and milder increase on the 
contralateral side (p  =  0.0001 and p  =  0.007, respectively), 
with individual significant increase of 20–50% in all studied 
ipsilateral regions, and of 30–40% in contralateral pyriform 
cortex, hippocampus and striatum (p < 0.05 in t-test). Curcumin 
pre-treatment also increased microglial activation score 
(Figure 1E) based on the αM integrin immunoreactivity. Regional 
assessment revealed an increase in activation score in the 
curcumin pre-treated group (Mixed Linear Model treating region 
as a repeated measure p  =  0.019) with significant increase of 
30–50% in hippocampus and thalamus (Figure 1E).
Immediate Post-treatment With Curcumin 
Reduces Brain Damage Following 
Neonatal HI-Insult
Compared to DMSO-treated animals, intraperitoneal injection 
of 200 μg/g BW curcumin straight after the HI-insult significantly 
reduced brain damage markers (tissue loss, TUNEL+ cell death, 
reactive astrogliosis, and microglial activation) at 48 h post-HI. 
As shown in Figures 2A–C, curcumin post-treatment markedly 
decreased ipsilateral forebrain tissue loss. Regional assessment 
presented in Figure 2A revealed strong decrease across the 
different forebrain regions (Mixed Linear Model treating region 
as a repeated measure, p  =  0.001). Treatment with curcumin 
significantly reduced tissue loss in relation to DMSO-treated 
littermates by 50–90% in cortex, pyriform cortex, hippocampus, 
striatum, external capsule, and overall forebrain area (p < 0.05 in 
t-test). Figure 2B shows large infarct in cortex and hippocampus 
of the DMSO-treated animal and its sparing in the curcumin-
treated littermate (Figure 2C).
A similar effect of the curcumin post-treatment was also 
observed for TUNEL+ cell death (Figures 2D–F). Figure 2D 
shows that curcumin treatment straight after 60  min HI 
significantly reduced the number of TUNEL+ cells compared 
to DMSO-treated littermates (Mixed Linear Model treating 
region as a repeated measure p  =  0.036), with individual 
significant decrease of 70–90% in cortex, pyriform cortex, 
hippocampus, and overall (p  <  0.05  in t-test). The TUNEL+ 
cells displayed the typical pyknotic nuclear morphology 
(Figure 2E-insert, ipsilateral hippocampus DMSO).
In addition to cell death and brain tissue loss, curcumin 
post-treatment also decreased HI-induced and predominantly 
ipsilateral reactive astrogliosis and microglial activation. Compared 
to DMSO-treated animals, their curcumin-treated littermates 
revealed less GFAP immunoreactivity (Figures 2G,M) with 
substantially reduced amount of GFAP+ astroglial processes 
(Figures 2H,I). Assessment across the different forebrain regions 
through Mixed Linear Model treating region as a repeated 
measure revealed a clear decrease on the ipsilateral, and milder 
reduction on the contralateral side (main effect p  =  0.005 and 
p  =  0.0001, respectively) with individual significant decrease 
of 30–50% in all six ipsilateral regions and overall, and of 30% 
in contralateral cortex and pyriform cortex (p  <  0.05, t-test).
Curcumin post-treatment had a similar effect on microglia 
activation score (Figure 2J) based on αM integrin immunoreactivity 
(Figures 2K,L). Regional assessment shown in Figure 2J revealed 
a reduction in activation score in the curcumin-treated group 
(Mixed Linear Model treating region as a repeated measure, 
main effect p  =  0.019), with significant decrease of 70–90% in 
all six individual ipsilateral brain regions (p  <  0.05  in t-test).
Compared to DMSO-treated animals, curcumin post-treated 
littermates had higher levels of myelination assessed through 
MBP immunoreactivity (Figure 2N), with individual significant 
increase of 20% in external capsule (p  <  0.05, t-test).
Curcumin post-treatment also reduced the levels of oxidative 
stress assessed through iNOS immunoreactivity, compared to 
DMSO-treated littermates, with individual significant decrease 
of 50% in hippocampus (Figure 2O, p  <  0.05, t-test).
Immediate Post-treatment With Curcumin 
Reduces Ipsilateral Volume Loss in Males, 
Females and Combined (Males + Females), 
Decreases Myelin Loss in Males, but Does 
Not Provide Functional Protection 
Assessed Through the Slipping Test
To evaluate the long-term effects of curcumin following immediate 
injection of 200  μg/g post HI, the levels of tissue loss were 
assessed through Nissl staining, the degree of myelination was 
evaluated through MBP immunoreactivity, and motor balance 
and co-ordination were assessed through the slipping test 
(Rocha-Ferreira et  al., 2018) at day 21 post HI (P28).
Intraperitoneal injection of 200 μg/g curcumin straight after 
HI decreased tissue loss in males at 21 days post HI compared 
to DMSO-treated littermates and untreated HI controls 
(Figure 3A). Immediate curcumin treatment had no effect on 
tissue loss in females compared to DMSO treated or untreated 
HI controls (Figure 3B). The levels of tissue loss in females 
were lower compared to males (Figure 3D). Although the 
differences did not reach significant values, the lower level of 
tissue loss in females suggests increased susceptibility of males 
to the insult. The levels of tissue loss in the curcumin group 
were significantly lower compared to DMSO-treated littermates 
and untreated HI controls (Figure 3C). Subregional assessment 
of tissue loss at 21  days post HI in males (Figure 3E) and 
combined (males + females) (Figure 3G) suggested that 
immediate treatment with curcumin at 200  μg/g immediately 
post HI reduced tissue damage in all studied regions with 
significant decrease in thalamus. Curcumin treatment did not 
affect subregional differences in tissue loss in females (Figure 3F).
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FIGURE 2 | Intraperitoneal injection of curcumin (200 μg/g BW) in P7 mice immediately post-HI significantly reduces tissue damage, cell death and glial response. 
(A–C) Ipsilateral forebrain Nissl staining (Cresyl-Violet, at rostral parietal level) - Quantification of ipsilateral brain tissue volume loss (A) at 48 h following HI-insult of 
DMSO (B) and curcumin (C) treated animals at 48 h following HI-insult. Curcumin treatment (n = 11) reduced volume loss compared to DMSO-treated littermates 
(n = 11) with significant, individual decrease (t-test) in cortex (p = 0.026), pyriform cortex (p = 0.011), hippocampus (p = 0.038), striatum (p = 0.020), external capsule 
(p = 0.015) and overall volume loss (p = 0.003). Mixed Linear Model treating region as a repeated measure revealed p = 0.001. (D–F) TUNEL+ staining of dying brain 
cells with fragmented DNA at 48 h following HI-insult – Quantification (D) (number of TUNEL+ cells per 20× eye-field, Mean + SEM) and histochemical overview of 
the ipsilateral forebrain in DMSO (E) and curcumin (F) treated animals. Note the typical pyknotic nuclear morphology of the TUNEL+ cells (Continued)
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Compared to untreated male HI control animals, curcumin 
post-treated littermates had an increase in myelination assessed 
through MBP immunoreactivity (Figure 3H) of 23% in striatum 
(p  <  0.05, two-way ANOVA). Immediate post-HI treatment 
with 200  μg/g curcumin did not affect myelin loss in females 
(Figure 3I) or combined (males + females) (Figure 3J).
Assessment of motor balance and co-ordination through 
slipping test at 21 days post HI of animals treated immediately 
after the insult with 200 μg/g curcumin, DMSO, or HI controls 
showed slightly decreased number of missed steps in curcumin-
treated males (Figure 3K), females (Figure 3L) and combined 
(males + females) (Figure 3M); however, the differences did 
not reach significance (Kruskal-Wallis test).
Immediate Post-treatment With Curcumin 
Reduces Brain Damage Following Neonatal 
HI-Insult in a Dose-Dependent Manner
Curcumin dose of 200  μg/g BW resulted in significant 
neuroprotection (Figure 2). To determine whether a lower dose 
of curcumin post-treatment immediately after the HI-insult 
would provide neuroprotective effects, three groups of animals 
were injected intraperitoneally with doses of 50, 22, and 10 μg/g 
BW curcumin in 0.5  μl/g BW DMSO. The control littermates 
in each group received the same volume of DMSO only. Brain 
damage markers (tissue loss, TUNEL+ cell death, reactive 
astrogliosis, and microglial activation) were assessed at 48  h 
post-HI. As shown in Figure 4, the dose of 50 μg/g (Figure 4A) 
significantly reduced the levels of microglial activation (Mixed 
Linear Model treating region as a repeated measure p = 0.035), 
with significant individual decrease of 50–65% in cortex, 
hippocampus, striatum, and external capsule (p  <  0.05, t-test). 
Similarly, the dose of 50 μg/g BW curcumin significantly reduced 
the levels of ipsilateral tissue loss (Mixed Linear Model treating 
region as a repeated measure p  =  0.0001), with significant 
individual decrease of 75–90% in cortex, hippocampus, and 
overall (Supplementary Figure S1A, p < 0.05, t-test). The levels 
of TUNEL+ cell death were also reduced by the dose of 50 μg/g 
BW curcumin (Mixed Linear Model treating region as a repeated 
measure p  =  0.016) with significant individual reduction of 
75–90% in hippocampus and external capsule (Supplementary 
Figure S1D, p  <  0.05, t-test). The dose of 50  μg/g markedly 
reduced also the levels of ipsilateral reactive astrogliosis (Mixed 
Linear Model treating region as a repeated measure p = 0.014), 
with significant individual reduction of 44–55% in pyriform 
cortex, hippocampus, thalamus, and external capsule 
(Supplementary Figure S1G, p  <  0.05, t-test). In a similar 
pattern, the dose of 50  μg/g significantly reduced contralateral 
astroglial activation (Mixed Linear Model treating region as 
a repeated measure p  =  0.005), with significant individual 
decrease in pyriform cortex (p  <  0.05, Supplementary 
Figure S1J). The doses of 22 and 10  μg/g BW curcumin did 
not have an effect on microglial activation (Figures 4B,C), 
ipsilateral volume loss, TUNEL+ cell death or reactive astrogliosis 
(Supplementary Figures S1B,C,E,F,H,I,K,L).
Delayed Post-treatment With Curcumin at 
60 and 120 min Post HI Reduces Brain 
Damage Following Neonatal HI-Insult
To investigate whether delayed application of curcumin would 
provide similar neuroprotection to the one achieved through 
immediate post-HI treatment, 200  μg/g BW curcumin was 
applied at 60 and 120  min following a neonatal HI insult and 
the brain damage markers were assessed at 48  h post HI. 
Treatment at 60 min reduced volume loss by 60–70% in cortex, 
hippocampus, striatum, thalamus, and overall compared to HI 
controls (Figure 5A, p < 0.05, Kruskal-Wallis test with Bonferroni 
correction), but had no effect compared to DMSO-treated 
littermates and no main effect of the treatment was observed. 
Application of curcumin at 60 min post HI significantly reduced 
TUNEL+ cell death compared to HI- and DMSO-treated 
littermates (Figure 5C, p  <  0.05, Kruskal-Wallis test). Pairwise 
comparison between the curcumin treated and HI groups 
revealed significant 80–90% decrease of the number of TUNEL+ 
cells in cortex, pyriform cortex, hippocampus and overall 
(Figure 5C, p  <  0.05, Kruskal-Wallis test with Bonferroni 
correction). Compared to DMSO-treated littermates curcumin 
FIGURE 2 | observed in the DMSO group (E- insert, hippocampus) and the lack of such cells in the curcumin group (F). Curcumin treatment reduced TUNEL+ cell 
death across all 6 examined forebrain regions, with significant, individual decrease (t-test) in cortex (p = 0.04), pyriform cortex (p = 0.049), hippocampus (p = 0.046), 
and overall (p = 0.048). Mixed Linear Model treating region as a repeated measure revealed p = 0.036. (G–I,M) GFAP immunoreactivity at 48 h - Quantification of the 
ipsilateral (D) and contralateral, non-occluded side (M) in optical luminosity values (OLV, Mean + SEM), and low magnification ipsilateral overview in DMSO (H) and 
curcumin (I) treated animals. The insert in H shows higher magnification of the dotted region in rostro-parietal cortex. Note the reduced levels of GFAP 
immunoreactivity in the curcumin treated animals, with significant, individual decrease (t-test) in ipsilateral cortex (p = 4 × 10−5), pyriform cortex (p = 0.004), 
hippocampus (p = 0.049), striatum (p = 0.001), thalamus (p = 0.001), external capsule (p = 0.009) and overall (p = 0.048) in G, and in contralateral cortex (p = 0.01) 
and pyriform cortex (p = 0.0004) in M. Mixed Linear Model treating region as a repeated measure revealed p = 0.005 for the ipsilateral, and p = 0.0001 for the 
contralateral side. (J–L) Activation of αM+ microglia – Ipsilateral αM microglial activation score (J, Mean + SEM) and low magnification ipsilateral overview in DMSO 
(K) and curcumin (L) treated animals. Note the strong microglial activation in DMSO-treated animals with αM+ cells showing phagocytic morphology at high 
magnification (K-insert, hippocampus), compared to the curcumin treated brains exhibiting a ramified phenotype (L-insert). Curcumin treatment reduced αM+ 
microglial activation across all six examined forebrain regions, with significant, individual decrease (t-test) in cortex (p = 0.03), pyriform cortex (p = 0.01), 
hippocampus (p = 0.03), striatum (p = 0.04), thalamus (p = 0.04), external capsule (p = 0.01) and overall (p = 0.02). Mixed Linear Model treating region as a repeated 
measure p = 0.019. DMSO (n = 11) and curcumin (n = 11) in all assessments. (N) MBP immunoreactivity at 48 h - Quantification of the ipsilateral external capsule 
and striatum in optical luminosity values (OLV, Mean + SEM). Note the increased levels of MBP immunoreactivity in the curcumin treated animals, with significant, 
individual increase (t-test) in ipsilateral external capsule (p = 0.045). Mixed Linear Model treating region as a repeated measure p = 0.056. (O) iNOS immunoreactivity 
at 48 h – Quantification of the number of iNOS+ cells in ipsilateral hippocampus (number of iNOS+ cells per 20× eye-field, Mean + SEM). Note the reduced number 
of iNOS+ cells (t-test) in the curcumin treated group compared to DMSO-treated littermates (p = 0.041). (*p < 0.05). Abbreviations: CTX, cerebral cortex; EC, external 
capsule; HIP, hippocampus; PYR, pyriform cortex; STR, striatum; THAL, thalamus. Scale bars: (B,C) = 2,000 μm; (E,F,H,I,K,L) = 1,000 μm; inserts = 62 μm.
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treatment at 60  min post HI significantly reduced TUNEL+ 
cell death by 80–90% in cortex, pyriform cortex, hippocampus 
and overall (Figure 5C, p  <  0.05, Kruskal-Wallis test with 
Bonferroni correction). Administration of curcumin at 60  min 
post HI reduced microglial activation compared to DMSO-
treated littermates and HI controls, although the main effect 




FIGURE 3 | Intraperitoneal injection of curcumin in P7 mice post-HI reduces ipsilateral volume loss in males, females and combined (males + females), decreases 
myelin loss in males, but does not provide functional protection assessed through slipping test. (A) Intraperitoneal injection of 200 μg/g curcumin straight after HI 
decreased tissue loss at 21 days post HI (P28) in males compared to DMSO-treated littermates and untreated HI controls (curcumin n = 11, DMSO n = 8, HI n = 9; 
curcumin vs. HI p = 0.0017, curcumin vs. DMSO p = 0.0003). (B) Curcumin treatment at 200 μg/g straight after HI did not affect tissue loss at 21 days post HI in 
females compared to DMSO-treated littermates or to untreated HI controls. (curcumin n = 8, DMSO n = 7, HI n = 8). (C) The levels of tissue loss in the curcumin 
treated animals decreased compared to DMSO-treated littermates and untreated HI controls (curcumin n = 19, DMSO n = 15, HI n = 17; curcumin vs. HI 
p = 0.0024, curcumin vs. DMSO p = 0.0014). (D) The level of tissue loss observed in females was lower compared to the males, however the differences did not 
reach significant values (p = 0.085). This suggests higher susceptibility of the males to HI insult. (E–G) Subregional assessment of tissue loss at 21 days post HI in 
males (E, curcumin n = 11, DMSO n = 8, HI n = 9), females (F, curcumin n = 8, DMSO n = 7, HI n = 8) and combined (males + females) (G, curcumin n = 19, DMSO 
n = 15, HI n = 17). Curcumin treatment with 200 μg/g immediately post HI resulted in a reduction of subregional tissue loss in all studied regions in males (E) and 
combined (males + females) (G) with significant differences observed in thalamus (males p = 0.0292, combined (males + females) p = 0.0242). (F) Curcumin 
treatment had no effect on subregional differences in tissue loss in females. (H–J) MBP immunoreactivity at 21 days post HI (P28). Quantification of the ipsilateral 
external capsule, striatum, and overall in optical luminosity values (OLV, Mean + SEM). (H) In males curcumin treatment with 200 μg/g immediately post HI resulted 
in increased levels of MBP immunoreactivity compared to untreated HI controls (curcumin n = 11, DMSO n = 8, HI n = 9), with significant differences in striatum 
(Two-way ANOVA with post hoc Tukey’s test, p = 0.042). In females (I, curcumin n = 8, DMSO n = 7, HI n = 8) and combined (males + females) (J, curcumin n = 19, 
DMSO n = 15, HI n = 17), immediate treatment with 200 μg/g curcumin had no effect on MBP immunoreactivity. (K–M) Curcumin treatment with 200 μg/g 
immediately post HI did not affect the number of missed steps (slipping test) at 21 days (P28) post HI in males (K, curcumin n = 13, DMSO n = 14, HI n = 14), 
females (L, curcumin n = 14, DMSO n = 15, HI n = 17) and combined (males + females) (M, curcumin n = 27, DMSO n = 29, HI n = 31). (*p < 0.05). Abbreviations: 
CTX, cerebral cortex; EC – external capsule; HIP – hippocampus; PYR, pyriform cortex; STR, striatum; THAL, thalamus.
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of treatment did not reach significance (Figure 5E). Curcumin 
treatment at 60  min post HI reduced microglial activation 
compared to HI controls with significant, individual decrease 
of 30% in external capsule (Figure 5E, p < 0.05, Kruskal-Wallis 
test with Bonferroni correction). Compared to DMSO-treated 
littermates curcumin treatment at 60  min post-HI reduced 
microglial activation with significant, individual decrease of 
90% in cortex (Figure 5E, p  <  0.05, Kruskal-Wallis test with 
Bonferroni correction). Curcumin application at 60  min post 
HI did not affect ipsilateral astroglial activation (Figure 5G).
Application of curcumin at 120  min post HI surprisingly 
increased the level of tissue loss but there was no significant 
main effect of treatment (p > 0.05, one-way ANOVA). However 
pairwise comparison revealed significant increase of 50% in 
volume loss in the cortex of curcumin treated compared to 
HI and to DMSO-treated littermates (Figure 5B, p  <  0.05, 
one-way ANOVA with Bonferroni correction). Delayed 
administration of curcumin at 120  min post HI significantly 
reduced the number of TUNEL+ cells compared to HI- and 
DMSO-treated littermates (Figure 5D, p  <  0.05, one-way 
ANOVA). Pairwise comparison revealed significant 60–90% 
decrease of TUNEL+ cell death in curcumin treated compared 
to HI animals in hippocampus, striatum and overall (Figure 5D, 
p < 0.05, one-way ANOVA with Bonferroni correction). Pairwise 
comparison between curcumin and DMSO-treated animals 
revealed significant 50–85% decrease of TUNEL+ cell death in 
hippocampus, striatum and overall (Figure 5D, p < 0.05, one-way 
ANOVA with Bonferroni correction). Administration of curcumin 
at 120  min post HI reduced microglial activation compared 
to HI- and DMSO-treated littermates (Figure 5F, p  <  0.05, 
Kruskal-Wallis test). Pairwise comparison between curcumin 
treated and HI animals revealed significant 40–60% decrease 
of microglial activation in pyriform cortex, hippocampus, striatum, 
thalamus, external capsule and overall (Figure 5F, p  <  0.05, 
Kruskal-Wallis test with Bonferroni correction). Pairwise 
comparison revealed significant 50% decrease of microglial 
activation in curcumin compared to DMSO-treated littermates 
in pyriform cortex, external capsule and overall (Figure 5F, 
p  <  0.05, Kruskal-Wallis test with Bonferroni correction). 
Administration of curcumin at 120 min post HI reduced ipsilateral 
reactive astrogliosis in cortex by 18% compared to HI and by 
38% compared to DMSO-treated littermates (Figure 5H, 
p < 0.05, Kruskal-Wallis test with Bonferroni correction); however, 
no main effect of the treatment was observed.
Post-treatment With Curcumin 
Immediately Post HI Has No Effect on the 
Levels of Cellular Proliferation at 48 h
To determine whether the neuroprotective effects of immediate 
curcumin treatment post HI are due to a boost of cellular 
proliferation, we  assessed the number of BrdU positive cells 
in P7 naïve animals, naïve animals injected with 200  μg/g 
curcumin, and HI animals injected immediately post insult with 
either 200  μg/g curcumin or DMSO. The number of BrdU+ 
cells in naïve untreated animals or naïve and HI animals treated 
with curcumin or DMSO did not differ between the groups 
in any of the tested brain regions (Figure 6A). Although curcumin 
treatment did not result in differences in cell proliferation levels 
in naïve or HI animals, we assessed its effect on the proliferation 
of different cell types, i.e., microglia, astroglia, oligodendrocyte 
precursors and neurons through double labeling for BrdU and 
IBA1 (microglia), GFAP (astroglia), NG2 (oligodendrocyte 
precursors), and NeuN (neurons) and calculation of the percentage 
of the double positive cells over the BrdU positive ones.
Curcumin treatment of naïve or HI animals immediately after 
insult did not affect the percentage of IBA1 and BrdU double 
positive (Figure 6B), GFAP and BrdU double positive (Figure 6C), 
NG2 and BrdU double positive (Figure 6D), or NeuN and BrdU 
double positive (Figure 6E) over BrdU positive cells per region 
and group. The percentage of proliferating microglia 
(Figures 6F,N,J), astroglia (Figures 6G,O,K), and oligodendrocytes 
(Figures 6H,P,L) was relatively low (10–20% of the total number 
of BrdU positive cells) compared to the neurons which comprised 
80–90% of the BrdU positive cells (Figures 6I,Q,M).
A B C
FIGURE 4 | Intraperitoneal injection of curcumin in P7 mice post-HI significantly reduces ipsilateral αM microglial activation score in a dose dependent manner.  
(A) Intraperitoneal injection of 50 μg/g BW curcumin decreased αM+ microglial activation compared to DMSO-treated littermates, with significant, individual 
decrease (t-test) in cortex (p = 0.038), hippocampus (p = 0.035), striatum (p = 0.035) and external capsule (p = 0.046). Mixed Linear Model treating region as a 
repeated measure revealed p = 0.035. (B,C) Intraperitoneal curcumin injection of 22 μg/g (B) or 10 μg/g (C) did not have an effect on αM+ microglial activation 
compared to DMSO-treated littermates. (A, curcumin 50 μg/g n = 8, DMSO n = 6, B, curcumin 22 μg/g n = 12, DMSO n = 10, C, curcumin 10 μg/g n = 11, DMSO 
n = 11). (*p < 0.05) Abbreviations: CTX, cerebral cortex; EC, external capsule; HIP, hippocampus; PYR, pyriform cortex; STR, striatum; THAL, thalamus.
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FIGURE 5 | Intraperitoneal injection of curcumin (200 μg/g BW) in P7 mice at 60 min or 120 min post-HI significantly reduces tissue damage, cell death and glial 
response. (A) Curcumin treatment at 60 min post HI (n = 8) reduced volume loss compared to HI controls (n = 10) with significant, individual decrease (Kruskal-
Wallis test with Bonferroni correction) in cortex (p = 0.036), hippocampus (p = 0.007), striatum (p = 0.003), thalamus (p = 0.005), and overall volume loss 
(p = 0.002). However, no main effect of the treatment was observed. No differences were registered between curcumin and DMSO (n = 7) treated littermates. (B) 
Administration of curcumin at 120 min post HI (n = 7) surprisingly increased the level of tissue loss however no significant main effect of treatment was observed. 
Pairwise comparison (one-way ANOVA with Bonferroni correction) revealed significant increase of volume loss in cortex in curcumin treated compared to HI (n = 7, 
p = 0.05) and to DMSO-treated littermates (n = 7, p = 0.017). (C) Curcumin treatment at 60 min post HI reduced TUNEL+ cell death compared to HI- and DMSO-
treated littermates (Kruskal-Wallis test). Pairwise comparison (Bonferroni correction) revealed significant decrease of TUNEL+ cell death in curcumin treated 
compared to HI animals in cortex (p = 0.064), pyriform cortex (p = 0.064), hippocampus (p = 0.003) and overall (p = 0.001). Pairwise comparison (Bonferroni 
correction) revealed significant decrease of TUNEL+ cell death in curcumin compared to DMSO-treated animals in cortex (p = 0.003), pyriform cortex (p = 0.013), 
hippocampus (p = 0.042), and overall (p = 0.012). (D) Administration of curcumin at 120 min post HI reduced TUNEL+ cell death compared to HI- and DMSO-
treated littermates (tone-way ANOVA, main effect p = 0.001). Pairwise comparison (Bonferroni correction) revealed significant decrease of TUNEL+ cell death in 
curcumin treated compared to HI animals in hippocampus (p = 0.002), striatum (p = 0.02), and overall (p = 0.001). Pairwise comparison (Bonferroni correction) 
revealed significant decrease of TUNEL+ cell death in curcumin compared to DMSO-treated littermates in hippocampus (p = 0.012), striatum (p = 0.022) and overall 
(p = 0.002). (E) Administration of curcumin at 60 min post HI reduced microglial activation compared to DMSO-treated littermates and HI controls, (Continued)
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FIGURE 6 | Intraperitoneal injection of curcumin (200 μg/g BW) in P7 mice immediately post-HI has no effect on the levels of proliferation at 48 h.  
(A) Assessment of the number of BrdU+ cells in P7 naïve untreated animals or naïve and HI animals treated with curcumin or DMSO did not show differences 
between the groups in any of the regions. (naïve n = 4, naïve + curcumin n = 5, HI + DMSO n = 7, HI + curcumin n = 8). (B) Curcumin treatment in naïve or HI 
animals immediately after insult did not affect the percentage of IBA1 and BrdU double positive over BrdU+ cells per region and group. The percentage of 
proliferating IBA1+ cells was low (10–20% of the BrdU+ cells). (C) The percentage of GFAP and BrdU double positive over BrdU+ cells per region and 
FIGURE 5 | although the main effect of treatment did not reach significance. However, compared to HI controls, curcumin treatment reduced microglial activation 
with significant, individual decrease (Kruskal-Wallis test with Bonferroni correction) in external capsule (p = 0.042). Compared to DMSO-treated littermates curcumin 
treatment at 60 min post-HI reduced microglial activation with significant, individual decrease (Kruskal-Wallis test with Bonferroni correction) in cortex (p = 0.028). (F) 
Administration of curcumin at 120 min post HI reduced microglial activation compared to HI- and DMSO-treated littermates (Kruskal-Wallis test, main effect 
p = 0.002). Pairwise comparison (Bonferroni correction) revealed significant decrease of microglia activation in curcumin treated compared to HI animals in pyriform 
cortex (p = 0.03), hippocampus (p = 0.002), striatum (p = 0.002), thalamus (p = 0.01), external capsule (p = 0.006) and overall (p = 0.004). Pairwise comparison 
(Bonferroni correction) revealed significant decrease of microglia activation in curcumin compared to DMSO-treated littermates in pyriform cortex (p = 0.018), 
external capsule (p = 0.022), and overall (p = 0.016). (G) Curcumin treatment at 60 min post HI did not affect ipsilateral reactive astrogliosis. (H) Administration of 
curcumin at 120 min post HI reduced ipsilateral reactive astrogliosis (Kruskal-Wallis test with Bonferroni correction) in cortex compared to HI (p = 0.049) and DMSO-
treated littermates (p = 0.006), however no main effect of the treatment was observed. (*p < 0.05). Abbreviations: CTX, cerebral cortex; EC – external capsule; HIP, 
hippocampus; PYR, pyriform cortex; STR, striatum; THAL, thalamus.
(Continued)
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Post-treatment With Curcumin Immediately 
Post-HI Decreases Phosphorylated 
STAT3 in Hippocampus, While Increasing 
Ipsilateral PHB Protein Levels at 1 h
Western Blot analyses for phosphorylated STAT3 Y705 (pSTAT3 
Y705) in ipsilateral and contralateral hippocampus from animals 
with no treatment (HI), DMSO- or 200 μg/g curcumin treatment 
and 1  h recovery demonstrated a slight bilateral increase in 
pSTAT3 Y705  in the DMSO-treated group compared to the HI 
controls; however, no significant differences were achieved 
(Figure 7A). Curcumin treatment significantly decreased pSTAT3 
Y705 on the contralateral side compared to DMSO-treated 
animals but did not show significant reduction compared to 
the HI group. Curcumin treatment did not result in significant 
changes in the ipsilateral side (Figure 7A). Western Blot analyses 
for phosphorylated STAT3 S727 (pSTAT3 S727) under the same 
conditions showed a slight ipsilateral increase of pSTAT3 S727 in 
the DMSO-treated compared to HI control animals; however, 
significant differences were not reached (Figure 7B). Curcumin 
treatment significantly reduced the levels of pSTAT3 S727 compared 
to the DMSO-treated animals, but had no effect in comparison 
to the HI littermate controls. No differences between the three 
groups were registered on the contralateral side (Figure 7B).
Western Blots analyses for PHB at 1  h post-HI of animals 
with HI, DMSO, or 200  μg/g curcumin treatment showed 
ipsilateral increase of PHB protein levels in the curcumin 
compared to DMSO-treated animals, but not to HI littermate 
controls (Figure 7C). No significant differences were observed 
between the DMSO-treated animals and the HI littermate 
controls. No differences between the three groups were registered 
on the contralateral side (Figure 7C).
The values represent relative densitometry compared to 
β-actin, which was used as the internal loading control.
DISCUSSION
As shown in the current study, in a Rice-Vannucci model of 
severe HI insult in P7 mice, immediate, as well as delayed (60 
or 120  min) application of curcumin after the HI insult clearly 
reduced forebrain cell death and tissue loss, as well as microglial 
and astroglial activation, in a dose dependent manner at 48  h 
post HI (Figures 2,4,5; Supplementary Figure S1). Our results 
show higher levels of MBP in the external capsule of the curcumin 
treated group at 48  h post HI and in the striatum of males at 
21  days post HI, suggesting protected myelination compared to 
the DMSO-treated littermates and untreated HI control littermates 
(Figures  2N,3H). These data were in line with other studies 
demonstrating that decrease in MBP loss is associated with 
neuroprotection of white matter following neonatal HI injury 
(Carlsson et  al., 2012; Cui et  al., 2017). Our data were also in 
line with the results from other groups registering maintenance 
of myelin structure and upregulation of MBP expression in the 
cerebellar white matter in a model of sodium arsenite induced 
neurotoxicity in developing rat cerebellum (Kaushal et al., 2014). 
Surprisingly, we  did not register similar effect in females 
(Figure 3I), which was also reflected in the combined (males 
+ females) assessment (Figure 3J). This is in line with the fact 
that male sex is a well-established risk factor for poor 
neurodevelopmental outcome after birth asphyxia and that the 
male hippocampus, normally larger than the female, undergoes 
a greater volume loss compared to females (Mayoral et al., 2009). 
We  also observed decrease in the number of iNOS positive 
cells in hippocampus following curcumin treatment post-HI 
(Figure 2O) suggesting reduction in oxidative stress. Our data 
is in line with previous studies in a rat model of neonatal HI 
where curcumin treatment prevented myelin loss, reduced iNOS 
expression and decreased caspase-3 dependent apoptosis (Cui 
et  al., 2017). Additionally, our results also show reduction in 
TUNEL+ cell death and tissue loss (Figure 2, Supplementary 
Figure S1) thus broadening the spectrum of assessed cell death.
Our experiments showed attenuation of tissue loss at 21  days 
post HI in males, females and combined (males + females), 
(Figures 3A–C), however the effects were more pronounced in 
the male group with subregional significant differences observed 
in thalamus of males and combined (males + females) 
(Figures 3E,G). The levels of damage in the female group were 
lower compared to the males (Figure 3D). Sex-related susceptibility 
to brain damage is probably the reason for no visible effect of 
the curcumin treatment in females (Figures 3B,F). Immediate 
post-HI treatment with curcumin slightly improved motor balance 
and co-ordination, assessed through the slipping test, in each 
gender separately and combined; however, the differences did not 
prove significance. This result is in line with previous data from 
our group suggesting that the sensitivity of the slipping test might 
not be suitable for assessment of motor balance and co-ordination 
differences following neonatal HI (Rocha-Ferreira et  al., 2018). 
At P28 the neonatal hippocampus is not fully developed (Semple 
FIGURE 6 | group was not affected by curcumin treatment in naïve or HI animals. The percentage of proliferating GFAP+ cells was low (10–20% of the BrdU+ cells). 
(D) The percentage of NG2 and BrdU double positive over BrdU+ cells per region and group was not affected by curcumin treatment in naïve or HI animals. The 
percentage of proliferating NG2+ cells was low (10–20% of the BrdU+ cells). (E) The percentage of NeuN and BrdU double positive over BrdU+ cells per region and 
group was not affected by curcumin treatment in naïve or HI animals. The percentage of proliferating NeuN+ cells comprised 80–90% of the BrdU+ cells and was 
the highest of all four studied cell types. (F,J,N) Immunofluorescence for rat polyclonal anti-BrdU (F,N) in green superimposed on the rabbit polyclonal anti-IBA1 
(J,N) in red, and nuclear DAPI fluorescence in blue (N). Note the co-localization of BrdU and IBA1 (white arrows) and the lack of such co- localization (empty 
arrows). (G,K,O) Immunofluorescence for rat polyclonal anti-BrdU (G,O) in green superimposed on the rabbit polyclonal anti-GFAP (K,O) in red, and nuclear DAPI 
fluorescence in blue (O). Note the co-localization of BrdU and GFAP (full arrows) and the lack of such co-localization (empty arrows). (H,L,P) Immunofluorescence 
for rat polyclonal anti-BrdU (H,P) in green superimposed on the guinea pig polyclonal anti-NG2 (L,P) in red, and nuclear DAPI fluorescence in blue (P). Note the 
co-localization of BrdU and NG2 (full arrows) and the lack of such co-localization (empty arrows). (I,M,Q) Immunofluorescence for rat polyclonal anti-BrdU (I,Q) in 
green superimposed on the mouse monoclonal anti-NeuN (M,Q) in red, and nuclear DAPI fluorescence in blue (Q). Note the high level of co-localization of BrdU 
and NeuN (full arrows) and the lack of such co-localization (empty arrows). Abbreviations: CTX, cerebral cortex; EC – external capsule; HIP – hippocampus; PYR, 
pyriform cortex; STR, striatum; THAL, thalamus. Scale bar: 126 μm.
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et  al., 2013) and it is possible that the damage is not reflected 
through motor and co-ordination challenges, thus assessments at 
later time points would be  more indicative. Additionally, some 
data suggest that unilateral hippocampal damage is compensated 
by the contralateral healthy hippocampus, thus, obscuring behavioral 
outcome (Warburton et  al., 2001; Jenkins et  al., 2006). Therefore, 
more robust cognitive behavioral tests assessing short- and long-
term memory post HI might prove more effective.
Curcumin is also a hormetin, thus demonstrating stimulatory 
properties at low doses and inhibitory ones at high doses. 
Therefore curcumin acts in a dose-dependent manner with 
lower doses being possibly more effective than higher ones, 
thus indicative of a hormetic response (Moghaddam et  al., 
2018). Dose response studies in vivo are essential for establishing 
whether a dietary factor affects organisms and cells via a hormetic 
mechanism. We  tested four different doses of curcumin, i.e., 
200, 50, 22, and 10 μg/g, and determined 50 μg/g as the minimal 
neuroprotective dose in neonatal HI brain damage (Figure 4, 
Supplementary Figure S1). As our data show no effect of the 
low doses (22 and 10  μg/g), and a protective effect at 50 and 
200  μg/g, at the tested doses curcumin does not seem to exert 
hormetic properties when applied post injury in neonatal HI.
Curcumin pre-treatment with 100  μg/g BW significantly 
attenuates hypoxia-induced cerebral transvascular leakage, with 
concomitant downregulation in the expression of brain NFκB 
levels (Himadri et  al., 2010). However, our results using the 
same pre-treatment curcumin dose but in the model of neonatal 
HI, increased the levels of brain damage markers (Figure 1) 
suggesting detrimental effect of the compound if present at the 
time of the insult. A possible explanation for the negative effect 
of curcumin in pre-treatment for HI can be  attributed to the 




FIGURE 7 | Intraperitoneal injection of curcumin (200 μg/g BW) in P7 mice immediately post-HI decreases phosphorylated STAT3 Y705 and S727 in hippocampus, 
while increasing ipsilateral PHB protein levels. (A) Western Blots for pSTAT3 (Y705) in ipsilateral and contralateral hippocampus from animals with HI, DMSO or 
200 μg/g curcumin treatment and 1 h recovery. β-actin protein levels served as control. Note the increase of STAT3 Y705 ipsi- and contralaterally in the DMSO-
treated group (19 and 16%, respectively) when compared to HI. Curcumin treatment decreases STAT3 Y705 protein levels ipsi- and contralaterally by 3 and 22%, 
respectively when compared to HI, and by 15 and 33% (p = 0.04) when compared to DMSO treatment. (B) Western Blots for pSTAT3 (S727) in ipsilateral and 
contralateral hippocampus from animals with HI, DMSO or 200 μg/g curcumin treatment and 1 h recovery. β-actin protein levels served as control. Note the increase 
of STAT3 S727 ipsi- and contralaterally in the DMSO-treated group (29 and 2%, respectively) when compared to HI. Curcumin treatment decreases STAT3 Y705 
protein levels ipsi- and contralaterally by 3 and 10%, respectively when compared to HI, and by 25% (p = 0.009) and 12% when compared to DMSO treatment.  
(C) Western Blots for PHB in ipsilateral and contralateral hippocampus from animals with HI, DMSO or 200 μg/g curcumin treatment and 1 h recovery. β-actin 
protein levels served as control. Note the ipsilateral 13 and 19% (p = 0.0026) increase of PHB protein levels in the curcumin treated animals compared to HI and 
DMSO, respectively. Interestingly curcumin treatment results in contralateral 23 and 12% decrease of PHB protein levels compared to HI and DMSO littermates, 
respectively. PHB levels in DMSO-treated littermates were reduced by 4% in the ipsilateral and by 13% in the contralateral side compared to littermate HI animals. 
The ratio between pSTAT3 or PHB and β-actin immunoreactivity is shown in arbitrary units (AU) set as 100% for the first line of curcumin treated animals on each of 
the blots. “R” represents relative densitometry compared to β-actin, which was used as the internal loading control.
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(Marchiani et  al., 2014; Akter et  al., 2019). Thus, when present 
during the HI insult in the neonate, curcumin possibly additionally 
reduces blood oxygen levels compared to the DMSO-treated 
littermates, and actually proves damaging. Interestingly, all damage 
markers are increased in hippocampus of the curcumin treated 
group, which might be  due to the high metabolic rate and 
oxygen demand of that region (Rocha-Ferreira and Hristova, 
2016). Another possibility for the contradiction in the pre-treatment 
results is the different developmental stage: in adults with hypoxia-
induced cerebral transvascular leakage all compensatory and 
antioxidant pathways are well established, compared to the 
underdeveloped neonatal brain subjected to HI injury.
Investigating the mechanisms behind the short-term 
neuroprotective effects of curcumin post-treatment following 
neonatal HI, we  explored whether the treatment had an effect 
on total and cell-specific proliferation. HI brain damage naturally 
boosts cell proliferation in the neonatal brain (Rocha-Ferreira 
and Hristova, 2016), however due to the magnitude of the 
damage, that proliferation is insufficient to provide the necessary 
repair. Curcumin is reported to stimulate cell differentiation 
(Gu et al., 2012; Mujoo et al., 2012; Chen et al., 2014). Therefore, 
we investigated whether the neuroprotective effects of curcumin 
in neonatal HI could be  attributed to an increase of the levels 
of cell proliferation thus stimulating repair. In line with previous 
studies (Rocha-Ferreira and Hristova, 2016), we observed some 
but not significant HI-induced increase in cell proliferation 
compared to naïve animals, and no significant effect of curcumin 
treatment. Thus, we  conclude that at 48  h following neonatal 
HI brain damage the neuroprotection provided by curcumin 
post-treatment is not a result of effects on cell proliferation.
The inhibitory effect of curcumin on the transcription 
properties of STAT3, a downstream target of IL6 as a main 
participant in HI brain damage (Rocha-Ferreira and Hristova, 
2016), is well documented (Alexandrow et al., 2012; Devi et al., 
2015; Patel et  al., 2019). Previous work from our group 
demonstrates that phosphorylated STAT3 Y705 is bilaterally 
upregulated in cortex and hippocampus following neonatal HI 
brain damage, and its inhibition results in neuroprotection 
(Hristova et al., 2016). Interestingly, at 1h post-HI, we observed 
only contralateral significant reduction in the protein levels of 
phosphorylated STAT3 Y705  in hippocampus of curcumin 
treated animals (Figure 7A) compared to DMSO-treated 
littermates but not to HI controls. Similar trend is also observed 
in the ipsilateral hippocampus; however, the differences were 
not significant. Detrimental effects of DMSO treatment have 
previously been reported (Galvao et  al., 2014) and our results 
suggest that DMSO treatment has a harmful effect which is 
counteracted by curcumin application (Figure 7A). STAT3 is 
an important regulator in astrocyte differentiation (Hong and 
Song, 2014). Although, at 1h post-HI, we  observed only 
contralateral reduction of pSTAT3 Y705 compared to DMSO-
treated animals, we  registered bilateral reduction of astroglial 
activation following post-treatment with 200  μg/g curcumin 
after neonatal HI (Figures 2G,M).
Curcumin treatment in a mouse model of stroke, reduced 
microglial activation and the infraction volume of the injured 
area compared to untreated controls (Liu et  al., 2017). In the 
same study, curcumin treatment reduced microglial gene 
expression of pro-inflammatory and oxidative stress markers 
such as TNFα, IL12 and iNOS, and in vitro incubation of 
LPS- or IFN γ activated microglia with curcumin reduced the 
release of pro-inflammatory cytokines (Liu et  al., 2017). Our 
data is in line with these findings suggesting that the observed 
reduction in tissue loss, cell death and glial response could 
rely on the ability of curcumin to resolve inflammation via 
downregulation of pro-inflammatory cytokines.
A small pool of STAT3 has recently been discovered in 
mitochondria (mito-STAT3), regulating mitochondrial electron 
transport chain, affecting mitochondrial metabolism and cellular 
function (Yang and Rincon, 2016). Mito-STAT3 activation is 
mediated by Ser727 phosphorylation and has been shown to 
be  crucial in immunological effector function and in cancer 
progression. Mito-Stat3 suppresses ROS formation during cancer 
genesis, suggesting that targeting Ser727 phosphorylation and mito-
STAT3 has strong potential in treating cancer. This effect of mito-
STAT3 could be  critical in neonatal HI as the formation of ROS 
is a major factor causing cell death during the secondary energy 
failure (Rocha-Ferreira and Hristova, 2016), although the mechanisms 
of action might not be  necessarily the same as in cancer genesis. 
Our data demonstrates ipsilateral reduction of phosphorylated 
STAT3 S727 in hippocampus following curcumin treatment post-HI 
compared to DMSO-treated animals but not to HI controls 
(Figure 7B) at 1h post-HI. This suggests a detrimental role of 
DMSO-treatment in neonatal HI brain damage, which is counteracted 
by curcumin. STAT3 regulates a metabolic function in mitochondria 
through STAT3 S727 phosphorylation, supporting Ras-dependent 
malignant transformation (Gough et al., 2009). Previous data from 
our lab have confirmed that global pharmacological inhibition of 
ERK phosphorylation is strongly neuroprotective in neonatal HI 
brain damage (Thei et  al., 2018). Thus, as mito-STAT3 is a 
downstream target of Ras/ERK (Yang and Rincon, 2016) our data 
were in line with these previous studies and reduced phosphorylation 
of STAT3 S727 could be  neuroprotective.
Our data demonstrates bilateral increase of phosphorylated 
STAT3 Y705 and S727 levels in the DMSO-treated animals 
compared to HI controls at 1h post-HI, which is in line with 
data from other groups reporting that low doses of DMSO 
induce caspase-3 independent neuronal death that involves 
apoptosis-inducing factor (AIF) translocation from mitochondria 
to the nucleus and poly-(ADP-ribose)-polymerase (PARP) 
activation (Galvao et  al., 2014). Thus our results showing 
decrease of only 3% ipsi- and 22% contralaterally for STAT3 
Y705, and of 3% ipsi- and 10% contralaterally for STAT3 
S727  in curcumin treated compared to HI control animals is 
likely a result of necessity for curcumin treatment to compensate 
for the detrimental effects of DMSO and provide 
further neuroprotection.
PHB is a mitochondrial protein which has emerged as an 
important modulator of neuronal survival in different injury 
models (Zhou et  al., 2012; Hernando-Rodríguez and Artal-Sanz, 
2018). PHB localizes to the inner membrane of mitochondria 
acting as a chaperone protein, but is also found in the nucleus, 
where it negatively regulates transcription. PHB is significantly 
increased in the whole cell and markedly decreased in the nuclear 
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matrix after curcumin treatment of HaCaT cells (Yang et  al., 
2014). Overexpression of PHB has been proven neuroprotective 
in a mouse model of middle cerebral artery occlusion (Kahl 
et  al., 2018). Knocking down PHB by siRNA partly increased 
the apoptosis level of the neuronal cell line PC12 stimulated by 
H2O2 (Xu et al., 2014). Our results at 1h post-HI show ipsilateral 
increase of the protein levels of PHB in hippocampus following 
curcumin treatment post-HI (Figure 7C). This is in line with 
the effects observed by other groups, generally associating increased 
PHB expression with decrease of cell death, amelioration of 
mitochondrial dysfunction and neuroprotection. However, it is 
unclear whether, similarly to STAT3 Y705 (Hristova et  al., 2016) 
PHB plays a different role in different cell types involved in 
neonatal HI, and whether its expression is time-dependent.
In conclusion, our data support a dose-dependent neuroprotection 
provided by immediate and delayed treatment with curcumin 
following neonatal HI injury. The precise mechanism of this 
protection is unclear; however, our results show effects of curcumin 
on oxidative stress and myelination, inflammation and transcription 
(STAT3 Y705) and mitochondrial dysfunction (STAT3 S727 and 
PHB). This makes curcumin an attractive therapeutic candidate 
in neonatal HI induced brain damage.
Although phase I  clinical trials have shown that curcumin 
is safe even at high doses (12 g/day), its future use and clinical 
application is limited as a result of its poor bioavailability due 
to poor absorption, rapid metabolism, and rapid systemic 
elimination (Anand et  al., 2007; Gupta et  al., 2013). Therefore, 
future experiments should focus on increasing curcumin 
bioavailability and solubility with the development of aqueous 
solutions for clinical application.
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SUPPLEMENTARY FIGURE S1 | Intraperitoneal injection of curcumin in P7 
mice post-HI significantly reduces in a dose dependent manner ipsilateral brain 
tissue volume loss, TUNEL+ cell death and ipsilateral and contralateral reactive 
astrogliosis. (A) Intraperitoneal injection of 50 μg/g BW curcumin decreased 
ipsilateral volume loss compared to DMSO treated littermates, with significant 
individual decrease (t-test) in cortex (p = 0.018), hippocampus (p = 0.025) and 
overall (p = 0.0004). Mixed Linear Model treating region as a repeated measure 
revealed p = 0.0001. (B,C) Intraperitoneal injection of 22 μg/g (B) and 10 μg/g  
(C) curcumin did not have an effect on volume tissue loss compared to DMSO 
treated littermates. (D) Intraperitoneal injection of 50 μg/g curcumin decreased 
ipsilateral TUNEL+ cell death compared to DMSO treated littermates, with 
significant individual decrease (t-test) in hippocampus (p = 0.007) and external 
capsule (p = 0.0001). Mixed Linear Model treating region as a repeated measure 
revealed p = 0.016. (E,F) Intraperitoneal injection of 22 μg/g (E) and 10 μg/g  
(F) curcumin did not have an effect on ipsilateral TUNEL+ cell death compared to 
DMSO treated littermates. (G) Intraperitoneal injection of 50 μg/g curcumin 
decreased ipsilateral reactive astrogliosis assessed though OLV of GFAP 
immunoreactivity compared to DMSO treated littermates, with significant individual 
decrease (t-test) in pyriform cortex (p = 0.025), hippocampus (p = 0.033), 
thalamus (p = 0.030) and external capsule (p = 0.031). Mixed Linear Model treating 
region as a repeated measure revealed p = 0.014. (H,I) Intraperitoneal injection of 
22 μg/g (H) and 10 μg/g (I) curcumin did not have an effect on ipsilateral TUNEL+ 
cell death compared to DMSO treated littermates. (J) Intraperitoneal injection of 
50 μg/g curcumin reduced contralateral reactive astrogliosis compared to DMSO 
treated littermates, with significant individual decrease (t-test) in pyriform cortex 
(p = 0.009). Mixed Linear Model treating region as a repeated measure revealed 
p = 0.005. (K,L) Intraperitoneal injection of 22 μg/g (H) and 10 μg/g (I) curcumin 
did not have an effect on contralateral astrogliosis compared to DMSO treated 
littermates. (A, curcumin 50 μg/g n = 8, DMSO n = 6, B, curcumin 22 μg/g n = 12, 
DMSO n = 10, C, curcumin 10 μg/g n = 11, DMSO n = 11) (*p < 0.05). 
Abbreviations: CTX, cerebral cortex; EC, external capsule; HIP, hippocampus; 
PYR, pyriform cortex; STR, striatum; THAL, thalamus.
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